Floatz logo

Fuzuloparib

Hypertension

Tulane UniversityPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Hypertension cohort.

Asset / SponsorPhaseRating
Hydrochlorothiazide
University of Kansas Medical Center
Phase 4BBB
VALSARTAN
University of Alabama at Birmingham
Phase 4BBB
Losartan
Rong Zhang
Phase 4BBB
AMLODIPINE
Jing Liu
Phase 4BBB
Trandolapril
University of Florida
Phase 4BBB

View all 50 →

Same molecule, other indications

Fuzuloparib is also rated in:

Obese Patients With Prostate Cancer DiseaseDormant
B
Indicative ·
60 / 100
View asset →
Chronic Postsurgical PainDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →